{
    "clinical_study": {
        "@rank": "75446", 
        "arm_group": [
            {
                "arm_group_label": "metformin", 
                "arm_group_type": "Experimental", 
                "description": "metformin"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Almost all antipsychotics can induce dyslipidemia, but no treatment has been established.\n      Metformin can improve lipid levels in obese patients. The investigators conducted a\n      randomized, placebo-controlled study to test the efficacy of metformin for\n      antipsychotic-induced dyslipidemia."
        }, 
        "brief_title": "Metformin for Treatment of Antipsychotic-induced Dyslipidemia", 
        "completion_date": {
            "#text": "June 2012", 
            "@type": "Actual"
        }, 
        "condition": "Dyslipidemia", 
        "condition_browse": {
            "mesh_term": "Dyslipidemias"
        }, 
        "detailed_description": {
            "textblock": "The study was designed as a double-blind randomized controlled trial, with research\n      assessors and patients intended to be blind to the intervention status. The staff members\n      performing the assessment were not involved in implementing any aspect of the\n      intervention.162 patients were randomized to one of two 24-week individual treatments:\n      metformin (1000mg/day)or placebo. Medications were provided in double-blind fashion.The\n      assessments include lipid levels, body weight, body mass index, fasting glucose, fasting\n      insulin and insulin resistance index."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Diagnostic and Statistical Manual of Mental Disorder-Fourth Edition (DSM-\u2163) criteria for\n        schizophrenia dyslipidemia after antipsycotic treatment the duration of illness was less\n        than 12 months taking only one antipsychotic stable outpatient the total score of Positive\n        and Negative Syndrome Scale (PANSS)\u226460.\n\n        -\n\n        Exclusion Criteria:\n\n        liver or renal diseases pregnant or lactating women cardiovascular diseases hypertension\n        or diabetes mellitus"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "162", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01778244", 
            "org_study_id": "RRWu"
        }, 
        "intervention": {
            "arm_group_label": "metformin", 
            "description": "1000mg/day for 24 weeks", 
            "intervention_name": "metformin", 
            "intervention_type": "Drug", 
            "other_name": "metformin"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Metformin", 
                "Antipsychotic Agents"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "schizophrenia; dyslipidemia", 
        "lastchanged_date": "January 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Changsha", 
                    "country": "China", 
                    "state": "Hunan", 
                    "zip": "410011"
                }, 
                "name": "Institute of Mental Health of The Second Xiangya Hospital, Central South University"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Metformin for Treatment of Antipsychotic-induced Dyslipidemia: a Randomized, Double-blind Study", 
        "other_outcome": {
            "measure": "body mass index", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "overall_official": {
            "affiliation": "Central South University", 
            "last_name": "Renrong Wu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "low-density lipoprotein cholesterol", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01778244"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Central South University", 
            "investigator_full_name": "Jingping Zhao", 
            "investigator_title": "professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "high-density lipoprotein cholesterol", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "adverse effects", 
                "safety_issue": "Yes", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Central South University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Central South University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2008", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}